Clinical Advances in
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), relatively unknown conditions just 2 decades ago, are now the most common causes of chronic liver disease worldwide, affecting an estimated 25% of the world's population. The collective epidemic of NAFLD and NASH closely parallels the epidemics of obesity and type 2 diabetes mellitus. As the prevalence of these conditions continues to increase, predictions are that the prevalence of NAFLD and NASH will also increase, creating unprecedented personal, clinical, and economic burdens. Early disease can be managed with modification of risk factors, and with off-label insulin sensitizers and/or antioxidants in some individuals. And while there are no approved drug regimens to treat NASH, the clinical trial pipeline is very active, with several agents in phase 3 trials. This curriculum will emphasize the importance of risk factor detection and early detection, diagnosis, and treatment -- through either regression or preventing progression of disease -- as means to halting the silent but deadly epidemic.
Supported by an independent educational grant from
Intercept Pharmaceuticals, Inc.
Steering Committee Chair
Chairman
Department of Medicine
Inova Fairfax Medical Campus
Betty and Guy Beatty Center for Integrated Research, Inova Health System
Falls Church, Virginia, United States
Professor of Experimental Hepatology and Honorary Consultant
Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle upon Tyne, United Kingdom
Professor
Division of Gastroenterology and Hepatology
Department of Medical Sciences
University of Turin
Turin, Italy
Director
Liver Institute Northwest
Clinical Professor
Elson S. Floyd College of Medicine
Washington State University
Spokane, Washington, United States
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
Professor
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong